Black patients are less likely to receive heart transplants

"Black patients were more likely to be sicker by the time they received the LVAD compared to white patients, making them more likely to be deemed ineligible for a heart transplant and taken off the waiting list," says Adrianne Frech. (Credit: DESIGNECOLOGIST/Unsplash)

Black patients with advanced heart failure are more likely to receive a left ventricular assist device later in their disease progression compared to white patients, according to a new study.

That can ultimately result in worse health outcomes.

Adrianne Frech, an associate professor in the University of Missouri School of Health Professions, is a medical sociologist interested in addressing inequalities within the health care system. She wondered if race affected a patient’s ability to access newer versions of left ventricular assist device (LVADs), devices implanted into the chest of a patient with advanced heart failure to help pump blood throughout the body.

For the new study, published in Progress in Transplantation, Frech and colleagues analyzed data from the United Network for Organ Sharing, or UNOS, spanning from 1999 to 2014 for patients who received a LVAD as a temporary “bridge” solution to their heart failure while on the waiting list to receive a permanent heart transplant.

She found that while access alone to these devices shows no racial inequality, underlying factors contribute to Black patients being less likely to receive a heart transplant compared to white patients.

“If you just look at that one piece of the puzzle, we found there was no significant difference for Black and white patients in accessing these devices as the technology improved over time,” Frech says.

“But as I dug deeper, where the inequalities emerged was when they got the device, as Black patients were more likely to be sicker by the time they received the LVAD compared to white patients, making them more likely to be deemed ineligible for a heart transplant and taken off the waiting list.”

As earlier implantation of LVADs is associated with better health outcomes. Frech’s research emphasizes the importance of preventive care and early treatment, while also highlighting how inequality can still persist even in health care systems designed to be fair.

“The process UNOS uses for determining who gets a heart transplant has many algorithms attached to it, so it is meant to be a completely fair process, but inequality is so pervasive in society that it still happens even without anyone intentionally trying to be racist or classist,” Frech says.

“The goal of the research is to articulate the more nuanced places where inequality happens, so that we can identify and target those areas to help reduce those inequalities.”

A step in the right direction occurred in December 2020, when the Centers for Medicare and Medicaid Services announced that individuals will be reimbursed for LVADs, even if they are not yet sick enough to require a heart transplant.

Frech says that while this policy change will benefit all individuals on Medicare and Medicaid, Black patients are more likely to be on public insurance programs than white patients.

“The traditional medical model for treating illness has typically focused on individual solutions for solving individual problems,” Frech says. “However, sociology introduces the idea that these are systematic problems that require systematic solutions. We know that inequality is harmful for human health, and there is evidence to suggest that the social systems we live in can play a role in causing disease.”

Source: University of Missouri